Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future

By  

Current Topics in Medicinal Chemistry, Vol. 16, Iss. 29, 2016-12 ,pp. : 3385-3403

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting the dopamine D₁ receptor in schizophrenia: insights for cognitive dysfunction

By Goldman-Rakic Patricia   Castner Stacy   Svensson Torgny   Siever Larry   Williams Graham  

Psychopharmacology, Vol. 174, Iss. 1, 2004-06 ,pp. : 3-16

Springer Publishing Company

Access to resources Recommend Favorite

Targeting the subtypes of breast cancer: rethinking investigational drugs

By Curigliano Giuseppe   Locatelli Marzia   Fumagalli Luca   Brollo Janaina   Munzone Elisabetta   Nolé Franco   Criscitiello Carmen   Goldhirsch Aron  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 2, 2012-02 ,pp. : 191-204

Informa Healthcare

Access to resources Recommend Favorite

Investigational A₃ adenosine receptor targeting agents

By Koscsó Balázs   Csóka Balázs   Pacher Pál   Haskó György  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 6, 2011-06 ,pp. : 757-768

Informa Healthcare

Access to resources Recommend Favorite

Sexual dysfunction in male schizophrenia: influence of antipsychotic drugs, prolactin and polymorphisms of the dopamine D2 receptor genes

By Zhang Xiang Rong   Zhang Zhi Jun   Zhu Rong Xin   Yuan Yong Gui   Jenkins Trisha A   Reynolds Gavin P  

Pharmacogenomics, Vol. 12, Iss. 8, 2011-08 ,pp. : 1127-1136

Future Medicine

Access to resources Recommend Favorite